Prevalence and Risk Factors of Sexually Transmitted Infections and Cervical Neoplasia in Women from a Rural Area of Southern Mozambique

Table 2

Prevalence of STIs and cervical neoplasia in women from Manhiça, Mozambique.

	𝑛/total	Prevalence (%)	95% Confidence interval
Gonococcal infection	34/250	14	(10; 19)
Syphilis (RPR & IgG)	31/258	12	(8; 17)
HPV DNA	100/253	40	(33; 46)
HIV antibodies	30/256	12	(8; 16)
HSV-2 antibodies	213/257	83	(78; 87)
Chlamydia trachomatis	19/253	8	(5; 11)
Trichomona vaginalis	78/254	31	(25; 37)
HBsAg antibodies	20/255	8	(5; 12)
Anti-HBc antibodies	160/256	63	(56; 68)
Any treatable STI*	128/252	51	(44; 57)
Any active STI**	179/254	70	(64; 76)
Cervical neoplasia	30/245	12	(8; 17)

*Any treatable STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis or chlamydia trachomatis.
**Any active STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis, chlamydia trachomatis, HPV or HIV infection.